Session Details
[28-53-pm1]Social Pharmacy 3, Regulatory sciences
Sat. Mar 28, 2026 1:10 PM - 3:10 PM JST
Sat. Mar 28, 2026 4:10 AM - 6:10 AM UTC
Sat. Mar 28, 2026 4:10 AM - 6:10 AM UTC
Room 53 (B306, Bldg. 1, Area 2 [3F])
Discusser: Takako Masuda, Ayumu Nagamine
[28-53-pm1-01]Interaction between tacrolimus and nirmatrelvir/ritonavir: A disproportionality analysis using the JADER database
○Ayako NULL Suzuki1,2, Tomoyuki Yamada3, Masahiro Kobayashi1,2 (1. Sch. Pharm., Kitasato Univ.,, 2. Pharm. Dept., Kitasato Univ. Hosp., 3. Pharm. Dept., Osaka Med. Pharm. Univ. Hosp.)
[28-53-pm1-02]Development of determination for N-nitrosodimethylamine by HPLC in the tablets
○Tatsuo Koide1, Hitomi Kanno1, Megumi Miyatsuji1, Ando Daisuke1, Tamaki Miyazaki1, Yoji Sato1 (1. National Institute of Health Sciences)
[28-53-pm1-03]Development of an Off-Target Evaluation Method for Novel Modalities with Potential Species-Specific Toxicity
○Nobumichi Ohoka1, Takenori Yamamoto1, Yasunori Uchida1, Tokuyuki Yoshida1, Takao Inoue1 (1. NIHS)
[28-53-pm1-04]Current status of package insert revisions based on PMDA consultations — Toward enhanced utilization —
○Sachi Miyahara1, Taisuke Ariyoshi2, Tomoko Chikura3, Yoshiko Nakano4, Yasuyuki Hattori4 (1. Bayer Yakuhin, 2. Novartis Pharma , 3. Astellas Pharma , 4. Daiichi Sankyo)
[28-53-pm1-05]Effects of primer cross-reactivity with human nucleic acids on viral nucleic acid detection
○Yoshinori Tsukumo1, Takuma Yamashita1, Takao Inoue1 (1. NIHS)
[28-53-pm1-06]Theoretical calculation of the amounts of nucleotide deletion impurities in oligonucleotides
○Yasunori Uchida1, Tokuyuki Yoshida1, Emi Saito2, Hirokazu Nankai2, Kaoru Karasawa3, Chie Inagaki3, Noriyuki Iwasaki3, Daisuke Higo4, Kentaro Takahara4, Takashi Osawa5, Takao Yamaguchi5, Kosuke Ito6, Junji Kawakami7, Satoshi Obika5, Takao Inoue1 (1. NIHS, 2. GeneDesign, Inc. dba Ajinomoto Bio-pharma Services, 3. SCIEX, 4. Thermo Fisher Scientific, 5. Grad. Sch. Pharm. Sci., Univ. of Osaka, 6. PMDA, 7. FIRST, Konan Univ.)
[28-53-pm1-07]International perspectives and operational challenges in inventory and stockpile strategies for safeguarding medicine supply
○Ken-ichi Izutsu1, Yukihiro Shibata1, Hiroaki Mamiya2 (1. SoP, IUHW, 2. CoPS, Ritsumeikan Univ.)
[28-53-pm1-08]The necessity of biological activity evaluations on quality control of peptide-drug conjugates
○Hashii Noritaka1, Yoko Hiruta1, Takashi Misawa1, Takuo Suzuki1, Hirotaka Nishimura1, Yosuke Demizu1, Akiko Ishii-Watabe1 (1. Natl. Inst. Health Sci.)
[28-53-pm1-09]A multi-institutional collaborative study on fine-tuning inter-institutional differences using a new particle standard in flow imaging methods
○Hiroko Shibata1, Yuki Kuruma2, Yukako Senga2, Tomohiro Takasugi3, Hirokazu Kito4, Kana Miyamoto5, Youko Kita6, Shinji Okabe7, Nanaka Goda8, Yuka Komine9, Akira Maruyama10, Yuriko Shibano11, Masako Nakano12, Naomi Ohbayashi13, Takaaki Kurinomaru14, Maho Sakurai15, Yuya Miyahara16, Shota Kojima17, Yuki Maeda18, Yasuyo Nozawa19, Chihiro Urashima20, Masato Kiyoshi1, Shinya Honda2, Tetsuo Torisu21, Susumu Uchiyama21, Akiko Ishii-Watabe1 (1. NIHS, 2. AIST, 3. Astellas Pharma Inc., 4. Eisai Co., Ltd., 5. Ono Pharmaceutical Co., Ltd., 6. Shionogi & Co., Ltd., 7. JCR Pharmaceuticals Co., Ltd., 8. Taiho Pharmaceutical Co., Ltd., 9. Daiichi Sankyo Co., Ltd., 10. Takeda Pharmaceutical Co., Ltd., 11. Chugai Pharmaceutical Co., Ltd., 12. Denka Co., Ltd., 13. Meiji Seika Pharma Co., Ltd., 14. U-Medico Inc., 15. Sumitomo Pharma Co., Ltd. , 16. Mitsubishi Tanabe Pharma Corporation., 17. Mochida Pharmaceutical Co., Ltd., 18. Shimadzu Corporation, 19. Japan Blood Products Organization, 20. Toray Research Center, Inc., 21. Grad. Sch. Eng, Osaka Univ.)
[28-53-pm1-10]Taiwanese pharmacists’ perceptions of e-patients’ use of online medication information: A cross-sectional study
○Chen Chung-Yu1, ニノヒラ アズミ2, 多根井 重晴2, 陳 福士2, 新井 一郎2, I-Jung Lee3, 大光 正男4 (1. Sch. Pharm., Kaohsiung Medical Univ., 2. Faculty Pharm. Sci., Nihon Pharmaceutical Univ., 3. Faculty Pharm. Sci., Yokohama University of Pharmacy, 4. DAIICHI UNIVERSITY OF PHARMACY)